7-Deazaguanine

Identification

Generic Name
7-Deazaguanine
DrugBank Accession Number
DB02245
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 150.138
Monoisotopic: 150.054160834
Chemical Formula
C6H6N4O
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with 7-Deazaguanine.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with 7-Deazaguanine.
AcetazolamideAcetazolamide may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
AdalimumabThe serum concentration of 7-Deazaguanine can be decreased when it is combined with Adalimumab.
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with 7-Deazaguanine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolopyrimidines
Sub Class
Not Available
Direct Parent
Pyrrolopyrimidines
Alternative Parents
Pyrimidones / Aminopyrimidines and derivatives / Pyrroles / Heteroaromatic compounds / Lactams / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Imine / Lactam / Organic 1,3-dipolar compound / Organic nitrogen compound
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyrrolopyrimidine (CHEBI:40308)
Affected organisms
Not Available

Chemical Identifiers

UNII
GPL8T5ZO3M
CAS number
7355-55-7
InChI Key
LOSIULRWFAEMFL-UHFFFAOYSA-N
InChI
InChI=1S/C6H6N4O/c7-6-9-4-3(1-2-8-4)5(11)10-6/h2H,1H2,(H3,7,9,10,11)
IUPAC Name
2-amino-3H,4H,5H-pyrrolo[2,3-d]pyrimidin-4-one
SMILES
NC1=NC2=C(CC=N2)C(=O)N1

References

General References
Not Available
PubChem Compound
4470573
PubChem Substance
46508935
ChemSpider
3668976
ChEMBL
CHEMBL219544
ZINC
ZINC000018187616
PDBe Ligand
7DG
PDB Entries
1il3 / 3iny / 4lvw / 7wie

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.76 mg/mLALOGPS
logP-1.2ALOGPS
logP-1.1Chemaxon
logS-1.7ALOGPS
pKa (Strongest Acidic)7.94Chemaxon
pKa (Strongest Basic)2.55Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area79.84 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity47.82 m3·mol-1Chemaxon
Polarizability13.91 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.983
Caco-2 permeable-0.6161
P-glycoprotein substrateNon-substrate0.7027
P-glycoprotein inhibitor INon-inhibitor0.9466
P-glycoprotein inhibitor IINon-inhibitor0.9689
Renal organic cation transporterNon-inhibitor0.6539
CYP450 2C9 substrateNon-substrate0.8281
CYP450 2D6 substrateNon-substrate0.7864
CYP450 3A4 substrateNon-substrate0.6018
CYP450 1A2 substrateNon-inhibitor0.5452
CYP450 2C9 inhibitorNon-inhibitor0.9613
CYP450 2D6 inhibitorNon-inhibitor0.9154
CYP450 2C19 inhibitorNon-inhibitor0.8879
CYP450 3A4 inhibitorNon-inhibitor0.8867
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9797
Ames testNon AMES toxic0.6003
CarcinogenicityNon-carcinogens0.9574
BiodegradationNot ready biodegradable0.9523
Rat acute toxicity2.5719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9824
hERG inhibition (predictor II)Non-inhibitor0.9463
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0ff0-6900000000-b7d32b2985cff4cc64ef
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-464cdd0b384605db2956
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-ead4577b5e1cec6c8ec1
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0900000000-c8f3479d85f20653e369
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pc0-6900000000-261d247c4cc37aa4d7ef
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052b-0900000000-b098c2d0df70a3dbd952
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kf-9100000000-65d6541e09820c14a394
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-129.14247
predicted
DeepCCS 1.0 (2019)
[M+H]+132.85295
predicted
DeepCCS 1.0 (2019)
[M+Na]+141.85835
predicted
DeepCCS 1.0 (2019)

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52